Bicara Therapeutics (BCAX) Capital Expenditures (2023 - 2026)

Bicara Therapeutics' Capital Expenditures history runs 4 years deep, the most recent figure standing at $60000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures changed N/A year-over-year to $60000.0; the TTM figure through Mar 2026 stood at $340000.0 (up 407.46% YoY), while the FY2025 annual figure was $280000.0, up 294.37% from the prior year.
• Capital Expenditures for Q1 2026 stood at $60000.0, down from $238000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $436000.0 in Q4 2023, with the low at $4000.0 in Q1 2024.
• The 4-year median for Capital Expenditures is $41000.0 (2024), against an average of $105875.0.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures sank 90.83% in 2024, then soared 495.0% in 2025.
• Bicara Therapeutics' Capital Expenditures stood at $436000.0 in 2023, then tumbled by 90.83% to $40000.0 in 2024, then jumped by 495.0% to $238000.0 in 2025, then slumped by 74.79% to $60000.0 in 2026.
• Business Quant data shows BCAX's Capital Expenditures at $60000.0 in Q1 2026, $238000.0 in Q4 2025, and $42000.0 in Q3 2025.